[Company Logo Image] Compound validation and profiling in vitro and in vivo
Improved clinical predictability of preclinical studies
Subcutaneous and orthotopic human xenografts
Genetically modified organ specific tumour models
Receptor tyrosine kinase-driven breast cancer model

         Preclinical Concept Validation

Angiogenesis in vivo Model

       

Syngeneic tumour models
Pharmacokinetic studies
  Toxicology (GLP)
  Histology (Frozen Sections and Paraffin Embedded Sections)

                      

Home Up vivoPharm Search Employment Feedback

Up Subcutaneous Orthotopic Syngeneic Angiogenesis

 

Histology 1
Histology 2

 
Organ

Cell Line

Prostate R-3327-AT1 (and other substrains), MAT-Lu
Glioma C6

Organ

Cell Line

Breast HC11 (NeuT), 4T1

 

In brief: drug-selected NeuT infected mammary epithelial cell populations are introduced into mammary fat pads of BALB/c syngeneic mice cleared of host tissue. Breast tumours develop within  a 3 to 4 week latency period and grow rapidly. The histology of the breast tumours is comparable to those observed in MMTV-NeuT transgenic mice. Most importantly, this tumour model is to our knowledge the first oncogene-driven model with a heterogeneous therapy response within a treatment group. This could be well demonstrated after treatment with Taxol(20 % complete responders) and Tamoxifen (15 % complete responders). These response rates are similar to those seen clinically. Furthermore, treatment with a small molecule KDR inhibitor resulted in a realistic clinically relevant number of 55% complete responders. Additionally the model is very suitable to test compound combination therapy.

Intraepithelial neoplasia with cysts

 

Adenocarcinoma

For price quotes please contact sales@vivoPharm.com

   

Send mail to webmaster@vivopharm.com with questions or comments about this web site.
Last modified: 18-Dec-2003